Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PRT036
MIFTS: 66

Peritonitis

Categories: Endocrine diseases, Gastrointestinal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Peritonitis

About this section

MalaCards integrated aliases for Peritonitis:

Name: Peritonitis 12 75 55 6 44 15 17 72 33
Retractile Mesenteritis 12 53 72
Sclerosing Mesenteritis 12 53 72
Peritoneal Retractile Mesenteritis 53 72
Acute Generalized Peritonitis 12 72
Primary Bacterial Peritonitis 12 72
Mesenteric Panniculitis 53 72
Idiopathic Sclerosing Mesenteritis 53
Liposclerotic Mesenteritis 53
Mesenteric Lipodystrophy 53
Mesenteric Lipogranuloma 53
Mesenteric Fibromatosis 53
Fibromatosis, Abdominal 72

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Gastrointestinal diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:8283
ICD9CM 35 567.8 567.89
MeSH 44 D010538
ICD10 33 K65 K65.9
UMLS 72 C0025470 C0029823 C0031154 more
Sources

Summaries for Peritonitis

About this section
NIH Rare Diseases : 53 Sclerosing mesenteritis is one of many terms that describes a spectrum of inflammatory disorders that affect the mesentery. The mesentery is the membrane that anchors the small intestine to the back of the abdominal wall. The condition mostly affects men between their 40s and 60s, but women and children can also be affected. It may result in a variety of symptoms including abdominal pain, nausea and vomiting, constipation or diarrhea, weight loss, and fever. Some people have an abdominal mass. The cause of the condition is poorly understood. Suggested possible causes have included previous abdominal surgery or trauma, autoimmunity, paraneoplastic syndromes, ischemic injury, and infection. Treatment depends on the symptoms in each person and may include the use of glucocorticoids, hormonal therapy (tamoxifen or progesterone), or other medications, either alone or in combination (i.e. glucocorticoids in combination with tamoxifen). Surgery may be needed for an obstruction, if present. Although there are case reports of patients with aggressive disease and fatalities, it appears that the condition usually remains stable or is slowly progessive. In some cases, the condition goes away on its own.

MalaCards based summary : Peritonitis, also known as retractile mesenteritis, is related to primary peritoneal carcinoma and tuberculous peritonitis. An important gene associated with Peritonitis is TMEM67 (Transmembrane Protein 67), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Iron and Cefoxitin have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and neutrophil, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A gastrointestinal system disease that involves inflammation of the peritoneum resulting from perforation of the gastrointestinal tract, which produces immediate chemical inflammation followed shortly by infection from intestinal organisms. Peritonitis can also result from appendicitis, diverticulitis, strangulating intestinal obstruction, pancreatitis, pelvic inflammatory disease, mesenteric ischemia, intraperitoneal blood, barium, or peritoneo-systemic shunts, drains, and dialysis catheters in the peritoneal cavity. The symptoms include abdominal pain and tenderness, fever, fluid in the abdomen, nausea, vomiting and low urine output.

Wikipedia : 75 Peritonitis is inflammation of the peritoneum, the lining of the inner wall of the abdomen and cover of... more...

Sources

Related Diseases for Peritonitis

About this section

Diseases related to Peritonitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2038)
# Related Disease Score Top Affiliating Genes
1 primary peritoneal carcinoma 34.9 MUC16 IL10 CXCL8
2 tuberculous peritonitis 34.1 TNF MUC16 CRP ALB ADA
3 familial mediterranean fever 33.6 TNF MEFV IL1B CRP
4 endometriosis 33.1 IL6 IL1B CXCL8 CCL2
5 juvenile rheumatoid arthritis 32.9 TNF IL6 IL1B CRP
6 systemic onset juvenile idiopathic arthritis 32.7 TNF MEFV
7 end stage renal failure 32.5 TNF IL6 CRP ALB
8 appendicitis 32.2 TNF LBP IL6 IL1B IL10 CXCL8
9 uremia 31.8 CRP B2M ALB
10 acute pancreatitis 31.5 IL6 IL10 CXCL8 CRP
11 hepatic encephalopathy 31.4 TNF IL6 ALB
12 peripheral vascular disease 31.4 IL6 CRP ALB
13 exanthem 31.4 TNF IL6 CRP
14 kidney disease 31.4 TMEM67 IL6 CRP CCL2 B2M ALB
15 duodenal ulcer 31.3 TNF IL1B CXCL8
16 respiratory failure 31.2 TNF CXCL8 CRP ALB
17 autoimmune disease 31.2 TNF IL6 IL1B IL10
18 protein-energy malnutrition 31.2 TNF IL6 ALB
19 abdominal tuberculosis 31.2 CRP ALB ADA
20 hydronephrosis 31.2 CCL2 B2M ALB
21 endometritis 31.1 TNF IL6 IL1B
22 peptic ulcer disease 31.1 TNF IL1B IL10 CXCL8
23 typhoid fever 31.1 TNF IL6 IL1B CRP ALB
24 purpura 31.1 TNF IL6 CRP
25 fasciitis 31.1 TNF IL6 CXCL8
26 nutritional deficiency disease 31.1 IL6 CRP ALB
27 bone disease 31.1 TNF IL6 IL1B B2M
28 intracranial hypertension 31.1 TNF IL1B AQP1
29 perinatal necrotizing enterocolitis 31.0 TNF IL6 IL1B CXCL8 CRP
30 stomatitis 31.0 TNF MEFV IL1B
31 acute respiratory distress syndrome 31.0 TNF IL6 IL1B CXCL8
32 streptococcal toxic-shock syndrome 31.0 TNF IL6 CXCL8
33 peripheral artery disease 31.0 IL6 CRP CCL2
34 echinococcosis 31.0 TNF TLR2 IL6 IL10
35 cerebrovascular disease 31.0 TNF IL6 ICAM1 CRP
36 uremic pruritus 30.9 IL6 IL1B CRP
37 fascioliasis 30.9 IL1B IL10 ALB
38 pelvic inflammatory disease 30.9 TLR2 CRP CCL2
39 cholangitis 30.9 TNF IL6 CRP ALB
40 colitis 30.8 TNF IL6 IL1B IL10 CXCL8
41 iga glomerulonephritis 30.8 IL6 CCL2 ALB
42 glomerulonephritis 30.8 IL1B ICAM1 CR1 CCL2 ALB
43 schistosomiasis 30.8 TNF IL10 ALB
44 vascular disease 30.8 TNF ITGAM IL6 CRP CCL2 ALB
45 carpal tunnel syndrome 30.8 IL6 IL1B B2M
46 acute cystitis 30.8 IL6 CXCL8 CRP CCL2 ALB
47 arthropathy 30.8 TNF CRP B2M
48 pericardial effusion 30.8 MUC16 IL6 CRP ADA
49 crohn's colitis 30.7 TNF IL1B CXCL8
50 atherosclerosis susceptibility 30.7 TNF IL6 ICAM1 CRP CCL2

Comorbidity relations with Peritonitis via Phenotypic Disease Network (PDN): (show all 12)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Vascular Insufficiency of Intestine
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Intestinal Obstruction
Intestinal Perforation Paralytic Ileus
Protein-Energy Malnutrition Respiratory Failure

Graphical network of the top 20 diseases related to Peritonitis:



Diseases related to Peritonitis
Sources

Symptoms & Phenotypes for Peritonitis

About this section

MGI Mouse Phenotypes related to Peritonitis:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.29 ADA AQP1 B2M CRP ICAM1 IL10
2 homeostasis/metabolism MP:0005376 10.28 ADA ALB AQP1 B2M CRP ICAM1
3 cellular MP:0005384 10.27 ADA ALB B2M ICAM1 IL10 IL6
4 hematopoietic system MP:0005397 10.25 ADA AQP1 B2M ICAM1 IL10 IL1B
5 immune system MP:0005387 10.21 ADA B2M CCL2 CRP ICAM1 IL10
6 digestive/alimentary MP:0005381 10.13 ADA ALB B2M ICAM1 IL10 IL6
7 endocrine/exocrine gland MP:0005379 10.11 ADA ALB AQP1 B2M ICAM1 IL10
8 integument MP:0010771 9.97 B2M ICAM1 IL10 IL1B IL6 ITGB2
9 mortality/aging MP:0010768 9.97 ADA ALB AQP1 B2M ICAM1 IL10
10 liver/biliary system MP:0005370 9.96 ADA ALB B2M IL10 IL6 LBP
11 neoplasm MP:0002006 9.56 ALB B2M ICAM1 IL10 IL1B IL6
12 skeleton MP:0005390 9.32 ADA AQP1 IL10 IL1B IL6 ITGB2
Sources

Drugs & Therapeutics for Peritonitis

About this section

Drugs for Peritonitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 289)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
2
Cefoxitin Approved Phase 4 35607-66-0 441199
3
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
4
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
5
Cefepime Approved, Investigational Phase 4 88040-23-7 5479537
6
Tigecycline Approved Phase 4 220620-09-7 5282044
7
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
8
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
9
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
10
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
11
Sulbactam Approved Phase 4 68373-14-8
12
Propranolol Approved, Investigational Phase 4 525-66-6 4946
13
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
14
Sultamicillin Approved, Investigational Phase 4 76497-13-7
15
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
16
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
17
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
18
Teicoplanin Approved, Investigational Phase 4 61036-62-2
19
Dalbavancin Approved, Investigational Phase 4 171500-79-1, 91097-81-3 122186
20
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
21
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
22
Cefazolin Approved Phase 4 25953-19-9 656510 33255
23
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
24
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
25
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
26
Atorvastatin Approved Phase 4 134523-00-5 60823
27
Lenograstim Approved, Investigational Phase 4 135968-09-1
28
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
29
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
30
tannic acid Approved Phase 4 1401-55-4
31
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
32
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
33
Losartan Approved Phase 4 114798-26-4 3961
34
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
35
Zinc Approved, Investigational Phase 4 7440-66-6 32051
36
Ornithine Approved, Nutraceutical Phase 4 70-26-8, 3184-13-2 6262
37
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
38
Isoleucine Approved, Investigational, Nutraceutical Phase 4 443-79-8, 73-32-5 6306
39
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
40 Vaccines Phase 4
41 Ferric Oxide, Saccharated Phase 4
42 Iron Supplement Phase 4
43 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
44 Cyclosporins Phase 4
45 Gentamicins Phase 4
46 Dialysis Solutions Phase 4
47 Gastrointestinal Agents Phase 4
48 Echinocandins Phase 4
49 Polymyxins Phase 4
50 beta-Lactamase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 337)
# Name Status NCT ID Phase Drugs
1 The Clinical Use of Probiotics in the Uremia Patients Under Chronic Peritoneal Dialysis Unknown status NCT01076426 Phase 4 Pro-biotics
2 PROPHYlactic Implantation of BIOlogic Mesh in Peritonitis (PROPHYBIOM) Unknown status NCT02277262 Phase 4
3 Antibiotics vs.Surgery in Acute Appendicitis;an Intention to Treat Prospective Randomised Study. The ASAA-study Unknown status NCT01421901 Phase 4 Ertapenem
4 A Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis Unknown status NCT00761098 Phase 4 Standard Care;Experimental
5 Prospective, Randomized, Open-Label Study of Topical Antibiotic Prophylaxis at the Catheter Exit Site: Continuous Daily Gentamicin Cream Versus Cyclical Gentamicin Cream and Mupirocin 2% Cream Alternating at Monthly Basis. Unknown status NCT00751374 Phase 4 gentamicin;gentamicin cream alternating with mupirocin cream
6 Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
7 Study of Safety, Immunogenicity and Immunological Memory of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome Unknown status NCT01346007 Phase 4
8 Prophylactic Administration of Antibiotics Before Radiofrequency Ablation for Hepatocellular Carcinoma: A Randomized Trial Unknown status NCT02534961 Phase 4 Cefazolin
9 Effect of Icodextrin on the Treatment Outcome of Peritoneal Dialysis Patients Completed NCT01044446 Phase 4 Icodextrin;glucose-based peritoneal dialysate
10 Bacteria Endotoxin in Peritoneal Dialysis Effluent as a Predictor of Relapsing, Recurrent, and Repeat Peritonitis Completed NCT01817309 Phase 4
11 Randomized Trial on Intravenous Antibiotics With Adjunctive Lavage for Severe Peritoneal-dialysis Related Peritonitis Completed NCT02926846 Phase 4 Intravenous vancomycin & gentamicin with adjunctive lavage;Intraperitoneal vancomycin & gentamicin
12 Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis Completed NCT02805049 Phase 4 Echinocandins
13 Randomized Controlled Trial Comparing Residual Kidney Function in Patients Undergoing Three or Four Exchanges CAPD Completed NCT01637792 Phase 4
14 A Randomized Controlled Double Blind Study Using Mupirocin Versus Polysporin Triple for the Prevention of Catheter-related Infections in Patients Treated With Peritoneal Dialysis Completed NCT00400595 Phase 4 Mupirocin ointment;Polysporin Triple
15 Randomized Double-Blid Placebo Controlled Trial Assessing Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis In Advanced Cirrhosis Completed NCT00359853 Phase 4 Oral norfloxacin
16 A Randomized, Multi-Center, Open Label Trial to Establish the Equivalence Between ANDY-Disc® (Fresenius Medical Care) and Ultrabag® (Baxter) in Patients on CAPD. [CAPD-2 Trial] Completed NCT00255619 Phase 4
17 A Multicenter, Randomized, Controlled Trial Comparing Cefepime Monotherapy Versus Combination of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-associated Peritonitis Completed NCT02872038 Phase 4 Cefepime;Cefazolin plus Ceftazidime
18 Phase 4 Study of Primary Use of the Vacuum Assisted Laparostomy in Treatment of Severe Peritonitis Completed NCT01531543 Phase 4
19 Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis Completed NCT01265173 Phase 4 Cefotaxime;Ceftriaxone;Ciprofloxacin
20 Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
21 Comparison of Daily Norfloxacin Versus Weekly Ciprofloxacin for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients Completed NCT01542801 Phase 4 Norfloxacin;ciprofloxacin
22 A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection Completed NCT00195351 Phase 4 tigecycline;ceftriaxone sodium + metronidazole
23 A Prospective, Double-blind, Multi Center, Randomized Clinical Study to Compare the Efficacy and Safety of Ertapenem 3 Days Versus Ampicillin-Sulbactam 3 Days in the Treatment of Localized Community Acquired Intra-abdominal Infection (IAI). (T.E.A. Study Three Days Ertapenem vs Three Days Ampicillin- Sulbactam) Completed NCT00630513 Phase 4 Ertapenem;Ampicillin-Sulbactam
24 A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection Completed NCT00230971 Phase 4 tigecycline;ceftriaxone plus metronidazole
25 Randomized, Long-Term Administration of pH-Neutral PD Solutions Containing Lactate (BALANCE) or Bicarbonate (BICAVERA) in Children Completed NCT01632046 Phase 4 lactate and bicarbonate buffered dialysis solutions
26 Effects of the Administration of Albumin in Patients With Cirrhosis and Acute Hepatic Encephalopathy. Completed NCT00886925 Phase 4 Albumin;Sodium chloride 0.9%
27 Beneficial Effect of Probiotics on Chronic Kidney Disease Completed NCT01391468 Phase 4
28 A Randomized Trial of Daily Chlorhexidine Care at the Exit Site in Peritoneal Dialysis Patients for Bacterial Decolonization and Prevention of Infection Completed NCT02446158 Phase 4 Chlorhexidine gluconate
29 Effect of Dexmedetomidine on Mortality, Duration of Mechanical Ventilation and Multi-organ Function in Sepsis Patients Under Lighter Sedation by Randomized Control Trial Completed NCT01760967 Phase 4 Dexmedetomidine
30 Extended Antibiotic Therapy in Postoperative of Laparoscopic Cholecystectomy Due to Acute Cholecystitis. Is it Necessary? Completed NCT02057679 Phase 4 Amoxicillin clavulanic;Placebo
31 Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients Completed NCT02940730 Phase 4 Dalbavancin via Intravenous Administration;Dalbavancin via Intraperitoneal Administration
32 The Clinical Effects of Korean Adapted APD in Automated Peritoneal Dialysis Patients Completed NCT01997385 Phase 4
33 Omega-3 Fatty Acids and Postoperative Complication After Colorectal Surgery Completed NCT00488904 Phase 4
34 Intestinal Decontamination With Rifaximin. Effects on the Inflammatory and Circulatory State in Patients With Cirrhosis and Ascites - A Randomised Controlled Clinical Study Completed NCT01769040 Phase 4 Rifaximin;placebo
35 Non Operative Treatment for Acute Appendicitis: Study on Efficacy and Safety of Antibiotic Treatment (Amoxicillin and Clavulanic Acid) in Patients With Right Sided Lower Abdominal Pain Completed NCT01096927 Phase 4 Amoxicillin and Clavulanic Acid
36 Prospective, Randomised European Multicentric Study, Comparing Enteral Stent Followed by Elective Surgery Versus Emergency Surgical Treatment in Malignant Colonic Obstruction Completed NCT00591695 Phase 4
37 Efficacy and Safety of a Very Low Protein Diet in Postponing Dialysis in Elderly: a Prospective Randomized Multicenter Controlled Study Completed NCT00388648 Phase 4 mixture of amino and keto acids
38 Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis in Patients With Acute Variceal Bleeding Completed NCT00838864 Phase 4 ceftrioxone;ceftrioxone
39 Effects of Angiotensin Converting Enzyme Inhibitors on Peritoneal Protein Loss and Solute Transport in Peritoneal Dialysis Patients Completed NCT01575652 Phase 4
40 The Use of Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis: a Multicenter, Open-label Randomized Clinical Trial Completed NCT01288794 Phase 4 Diuretics plus human albumin;Diuretics (standard medical treatment)
41 Cost- Effectiveness and Cost-utility of Laparoscopic Versus Open Repair of Ventral Hernia: Randomized Clinical Trial Completed NCT01778387 Phase 4
42 Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial Completed NCT01722578 Phase 4 L-ornithine L-aspartate;Placebo
43 Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis Completed NCT00939952 Phase 4 ertapenem
44 Defining the Optimal Duration of Treatment for "Low-Risk" Peritoneal Dialysis-Related Peritonitis Recruiting NCT03675854 Phase 4 Cefazolin
45 The Efficacy of Prolonged Antibiotic Therapy for the Prevention of Relapsing Peritonitis in Peritoneal Dialysis Patients With High Dialysis Effluent Bacterial DNA Fragment Levels Recruiting NCT02593201 Phase 4 Extended antibiotics (cefazolin or ceftazidime);Usual antibiotics (cefazolin or ceftazidime)
46 Prospective Trial Comparing the Performance Profiles of Two Non-Cross-Linked Porcine Dermal Matrices in Abdominal Wall Reconstruction Recruiting NCT02228889 Phase 4
47 Efficacy and Safety of Local Application of Chlorhexidine Gluconate Versus Mupirocin Ointment in the Prevention of Peritoneal Dialysis-Related Infection: A Double-Blind, Stratified Randomized Controlled Trial Recruiting NCT02547103 Phase 4
48 Open-label, Randomized, Controlled, With Blind Assessor, Study to Assess Efficacy and Safety of Rheosorbilact®, Solution for Infusion, in Comparison With Ringer's Lactate,Solution for Infusion, in a Complex Therapy of Peritonitis. Recruiting NCT03771170 Phase 4 Rheosorbilact®;Ringer lactate
49 FEcal Transplant, a Hope to Eradicate Colonization of Patient Harboring eXtreme Drug Resistant Bacteria? Recruiting NCT03029078 Phase 4 fecal microbiota transplant
50 Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment: a Double-blind Randomized Placebo-controlled Trial Recruiting NCT03024684 Phase 4 Atorvastatin;Placebo Oral Tablet

Search NIH Clinical Center for Peritonitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Albumin Human, USP
ALBUMIN,AGGREGATED
ALBUMIN,EGG
ALBUMIN,HUMAN INJ
ALBUMIN,MICROSPHERE HUMAN SERUM
Caspofungin
Cefoxitin
Clindamycin
Micafungin
Norfloxacin
Ofloxacin
Piperacillin
Sulfamethoxazole
Tazobactam

Cochrane evidence based reviews: peritonitis

Sources

Genetic Tests for Peritonitis

About this section
Sources

Anatomical Context for Peritonitis

About this section

MalaCards organs/tissues related to Peritonitis:

41
Liver, Colon, Neutrophil, Small Intestine, Kidney, Testes, Lung
Sources

Publications for Peritonitis

About this section

Articles related to Peritonitis:

(show top 50) (show all 29896)
# Title Authors PMID Year
1
Mortality and risk stratification in patients with Clostridium difficile-associated diarrhoea. 9 38
19508548 2010
2
Predictors of patient survival in continuous ambulatory peritoneal dialysis: 10-year experience in 2 major centers in Tehran. 9 38
20081304 2010
3
Peritonitis from peg tube insertion in surgical intensive care unit patients: identification of risk factors and clinical outcomes. 9 38
19430836 2009
4
Endothelial dysfunction in peritoneal dialysis patients with and without failed renal transplants. 9 38
19917360 2009
5
AGE-modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis. 9 38
19401390 2009
6
Peritoneal resorption capacity for the inflammatory mediators in acute experimental Staphylococcus aureus peritonitis. 9 38
19669960 2009
7
Primary peritonitis due to brucellosis mimicking tuberculous peritonitis. 9 38
19530047 2009
8
Albumin administration in patients with severe sepsis due to secondary peritonitis. 9 38
19467947 2009
9
[Peritonitis in the course of peritoneal dialisis caused by Haemophilus influenzae with BLNAR phenotype]. 9 38
19580200 2009
10
Effect of the combination of fibrin glue and growth hormone on intestinal anastomoses in a pig model of traumatic shock associated with peritonitis. 9 38
19132439 2009
11
Systemic and intraperitoneal proinflammatory cytokine profiles in patients on continuous ambulatory peritoneal dialysis. 9 38
19886317 2009
12
Is decline in serum albumin an ominous sign for subsequent peritonitis in peritoneal dialysis patients? 9 38
19886340 2009
13
[The prognostic role of interleukin-6 in peritoneal exudate of patients with diffuse peritonitis]. 9 38
20020622 2009
14
Fungal peritonitis in peritoneal dialysis: risk factors and prognosis. 9 38
19142806 2009
15
Concentration of adipokines in peritoneal effluent: a new marker of acute peritonitis in peritoneal dialysis patients? 9 38
18708547 2008
16
Clinical characteristics of lower bowel perforation with chronic renal failure. 9 38
19102359 2008
17
The relationship of p1 and lewis antigens with peritoneal dialysis-related Escherichia coli peritonitis. 9 38
18552251 2008
18
The outcome for pediatric patients on peritoneal dialysis. 9 38
18587728 2008
19
TLR2-dependent MyD88 signaling contributes to early host defense in murine Enterococcus faecium peritonitis. 9 38
18354210 2008
20
[Peritonitis related to peritoneal dialysis: evaluation of 179 attacks]. 9 38
18697424 2008
21
Relation of demographic, clinic and biochemical parameters to peritonitis in peritoneal dialysis. 9 38
18336516 2008
22
A leptin serum concentration less than 10 ng/ml is a predictive marker of outcome in patients with moderate to severe secondary peritonitis. 9 38
18525209 2008
23
Proteomic analysis of peritoneal dialysate fluid in patients with dialysis-related peritonitis. 9 38
18791950 2008
24
Fas expression on peritoneal macrophages during continuous ambulatory peritoneal dialysis peritonitis. 9 38
18350449 2008
25
Streptococcus salivarius bacteremia and spontaneous bacterial peritonitis in liver transplantation candidates. 9 38
17969206 2007
26
Reduced residual renal function is a risk of peritonitis in continuous ambulatory peritoneal dialysis patients. 9 38
17517797 2007
27
Influence of peritoneal dialysis training nurses' experience on peritonitis rates. 9 38
17699477 2007
28
Peritonitis, peritoneal inflammation and membrane permeability: a longitudinal study of dialysate and serum MCP-1 in stable patients on peritoneal dialysis. 9 38
17557268 2007
29
Adherence to peritoneal dialysis training schedule. 9 38
17035375 2007
30
Collagenase 2/matrix metalloproteinase 8 in critically ill patients with secondary peritonitis. 9 38
17224788 2007
31
Comparison of incidence of peritonitis between peritoneal dialysis solution types. 9 38
17409770 2007
32
Impact of nutritional status on peritonitis in CAPD patients. 9 38
17179509 2007
33
Systemic and intraperitoneal proinflammatory cytokines profiles in patients on chronic peritoneal dialysis. 9 38
18928158 2007
34
Clinical predictors of ongoing infection in secondary peritonitis: systematic review. 9 38
17102920 2006
35
Malnutrition-inflammation score is a useful tool in peritoneal dialysis patients. 9 38
17047239 2006
36
Anti-inflammatory effects of a novel peptide designed to bind with NF-kappaB p50 subunit. 9 38
17049124 2006
37
Compartmentalization of interleukin-6 response in a patient with septic meningococcal peritonitis. 9 38
16988004 2006
38
Adenosine is upregulated during peritonitis and is involved in downregulation of inflammation. 9 38
16788688 2006
39
Risk factors of first peritonitis episode in Thai CAPD patients. 9 38
17044465 2006
40
Survival and technical failure in a large cohort of Thai CAPD patients. 9 38
17044460 2006
41
Mast cell chymase induces expression of chemokines for neutrophils in eosinophilic EoL-1 cells and mouse peritonitis eosinophils. 9 38
16690053 2006
42
Peritonitis in childhood: clinical relevance of cytokines in the peritoneal exudate. 9 38
16685614 2006
43
Timely transfer of peritoneal dialysis patients to hemodialysis improves survival rates. 9 38
16429841 2006
44
Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. 9 38
16538876 2006
45
Dialysate CA125 levels in children on continuous peritoneal dialysis. 9 38
16133054 2005
46
The impact of topical mupirocin on peritoneal dialysis infection in Singapore General Hospital. 9 38
16046516 2005
47
Risk factors for peritonitis in pediatric peritoneal dialysis: a single-center study. 9 38
16082548 2005
48
[A contemporary situation in the antimicrobial treatment of the secondary peritonitis]. 9 38
16250620 2005
49
The impact of topical mupirocin on peritoneal dialysis infection rates in Singapore General Hospital. 9 38
15855200 2005
50
A risk analysis of continuous ambulatory peritoneal dialysis-related peritonitis. 9 38
16022095 2005
Sources

Variations for Peritonitis

About this section

ClinVar genetic disease variations for Peritonitis:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 TMEM67 NM_153704.5(TMEM67): c.1843T> C (p.Cys615Arg) single nucleotide variant Pathogenic/Likely pathogenic rs201893408 8:94808198-94808198 8:93795970-93795970
2 TMEM67 NM_153704.5(TMEM67): c.1321C> T (p.Arg441Cys) single nucleotide variant Pathogenic/Likely pathogenic rs752362727 8:94798483-94798483 8:93786255-93786255
Sources

Expression for Peritonitis

About this section
Search GEO for disease gene expression data for Peritonitis.
Sources

Pathways for Peritonitis

About this section

Pathways related to Peritonitis according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 14.04 TNF TLR2 MUC16 MEFV LBP ITGB2
2
TGF-Beta Pathway 64
Show member pathways
 13.61 TNF ITGB2 ITGAM IL6 IL1B IL10
3
Akt Signaling 64
Show member pathways
 13.5 TNF TLR2 ITGB2 ITGAM IL6 IL1B
4
Cytokine Signaling in Immune system 66
Show member pathways
 13.43 TNF LBP ITGB2 ITGAM IL6 IL1B
5
Toll-like Receptor Signaling Pathway 37 1
Show member pathways
 13.18 TNF TLR2 MEFV LBP IL6 IL1B
6
Human cytomegalovirus infection 37
Show member pathways
 13.08 TNF TLR2 IL6 IL1B ICAM1 CXCL8
7
Allograft rejection 37 1
Show member pathways
 13 TNF ITGB2 IL6 IL1B IL10 ICAM1
8
NF-kappaB Signaling 4
12.69 TNF TLR2 ITGB2 IL1B IL10 CCL2
9
Th17 cell differentiation 37
Show member pathways
 12.66 TNF TLR2 IL6 IL1B IL10
10
Immune response IL-23 signaling pathway 22
Show member pathways
 12.66 TNF IL6 IL1B IL10 CCL2
11
T cell receptor signaling pathway 37
Show member pathways
 12.58 TNF IL6 IL1B IL10
12
IL-17 Family Signaling Pathways 65
Show member pathways
 12.48 TNF TLR2 IL6 IL1B CXCL8 CCL2
13
Selenium Micronutrient Network 1
Show member pathways
 12.41 TNF IL6 IL1B ICAM1 CRP CCL2
14
Toll Comparative Pathway 64
Show member pathways
 12.4 TNF LBP IL6 IL1B CXCL8
15
Human T-cell leukemia virus 1 infection 37
12.38 TNF ITGB2 IL6 ICAM1
16
IL-1 Family Signaling Pathways 65
Show member pathways
 12.34 TNF TLR2 IL6 IL1B CXCL8
17
G-protein signaling Regulation of p38 and JNK signaling mediated by G-proteins 22
Show member pathways
 12.34 TLR2 ITGB2 ITGAM IL1B ICAM1 CXCL8
18
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.33 TNF IL6 IL1B IL10 CXCL8
19
Toxoplasmosis 37
Show member pathways
 12.33 TNF TLR2 ITGB2 ITGAM IL1B IL10
20
Diseases associated with the TLR signaling cascade 66
Show member pathways
 12.32 TNF TLR2 IL6 CXCL8
21
Bacterial infections in CF airways 22
Show member pathways
 12.32 TNF TLR2 LBP IL6 IL1B CXCL8
22
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.29 TNF IL6 IL1B IL10 CXCL8
23
C-type lectin receptor signaling pathway 37
Show member pathways
 12.27 TNF IL6 IL1B IL10
24
Tuberculosis 37
12.27 TNF TLR2 LBP ITGB2 ITGAM IL6
25
Immune response IFN gamma signaling pathway 22
Show member pathways
 12.19 IL6 IL1B IL10 ICAM1 CXCL8 CCL2
26
Th1 Differentiation Pathway 65
Show member pathways
 12.19 TNF TLR2 IL6 IL1B IL10
27
Fluid shear stress and atherosclerosis 37
12.17 TNF IL1B ICAM1 CCL2
28
Immune response Lectin induced complement pathway 22
Show member pathways
 12.15 ITGB2 ITGAM CRP CR1
29
Microglia Activation During Neuroinflammation: Overview 65
Show member pathways
 12.14 TNF TLR2 ITGB2 ITGAM IL6 IL1B
30
TNF signaling pathway 37
12.12 TNF IL6 IL1B ICAM1 CCL2
31
Spinal Cord Injury 1
12.1 TNF IL6 IL1B ICAM1 CXCL8 CCL2
32
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
12.08 TNF ITGAM IL6 IL10
33
NF-kappa B signaling pathway 37
12.06 TNF LBP IL1B ICAM1 CXCL8
34
Hematopoietic cell lineage 37
12.04 TNF ITGAM IL6 IL1B CR1
35
AGE-RAGE signaling pathway in diabetic complications 37
12 TNF IL6 IL1B ICAM1 CXCL8 CCL2
36
Cytokine production by Th17 cells in CF (Mouse model) 22
Show member pathways
 11.98 LBP IL6 ICAM1 CXCL8
37
Staphylococcus aureus infection 37
11.97 ITGB2 ITGAM IL10 ICAM1
38
Phagocytosis of Microbes 64
11.93 TLR2 ITGB2 ITGAM CR1
39
Amoebiasis 37
11.93 TNF TLR2 ITGB2 ITGAM IL6 IL1B
40
Salmonella infection (KEGG) 37
11.92 LBP IL6 IL1B CXCL8
41
Innate Lymphoid Cell Differentiation Pathways 65
11.9 TNF ITGAM IL1B IL10
42
Dendritic Cells Developmental Lineage Pathway 65
11.9 TNF ITGAM IL6 IL1B IL10
43
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.87 TNF IL6 IL1B IL10 CCL2
44
Pertussis 37
11.86 TNF ITGB2 ITGAM IL6 IL1B IL10
45
IL-6 signaling pathway 1
Show member pathways
 11.85 LBP IL6 CRP
46
Glucocorticoid receptor regulatory network 1
11.83 IL6 ICAM1 CXCL8
47
Rheumatoid arthritis 37
11.83 TNF TLR2 ITGB2 IL6 IL1B ICAM1
48
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.8 TNF IL6 IL1B ICAM1 CXCL8
49
Lung fibrosis 1
11.8 TNF IL6 IL1B CXCL8 CCL2
50
amb2 Integrin signaling 1
11.64 TNF ITGB2 ITGAM IL6 ICAM1
Sources

GO Terms for Peritonitis

About this section

Cellular components related to Peritonitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.72 TNF TLR2 ITGB2 ITGAM ICAM1
2 external side of plasma membrane GO:0009897 9.63 TNF ITGB2 ITGAM ICAM1 B2M ADA
3 cell surface GO:0009986 9.61 TNF TLR2 LBP ITGB2 ITGAM ICAM1
4 extracellular space GO:0005615 9.47 TNF MUC16 LBP ITGAM IL6 IL1B
5 integrin alphaM-beta2 complex GO:0034688 9.37 ITGB2 ITGAM
6 extracellular exosome GO:0070062 10.1 MUC16 LBP ITGB2 ITGAM IL1B ICAM1
7 extracellular region GO:0005576 10 TNF MUC16 LBP IL6 IL1B IL10

Biological processes related to Peritonitis according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of angiogenesis GO:0045766 9.99 ITGB2 IL1B CXCL8 AQP1
2 response to lipopolysaccharide GO:0032496 9.97 TLR2 LBP IL1B IL10 ICAM1
3 response to drug GO:0042493 9.97 IL10 ICAM1 B2M AQP1 ADA
4 positive regulation of DNA-binding transcription factor activity GO:0051091 9.95 TNF IL6 IL1B IL10
5 neutrophil chemotaxis GO:0030593 9.93 ITGB2 IL1B CXCL8 CCL2
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 TNF ICAM1 CCL2
7 cellular response to interleukin-1 GO:0071347 9.91 ICAM1 CXCL8 CCL2
8 defense response to Gram-positive bacterium GO:0050830 9.91 TNF TLR2 LBP IL6 CRP
9 response to insulin GO:0032868 9.9 TLR2 IL10 ICAM1
10 cellular response to organic cyclic compound GO:0071407 9.9 TNF IL1B CCL2
11 humoral immune response GO:0006959 9.88 TNF IL6 CCL2
12 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 TNF TLR2 ITGB2 IL6 IL1B ICAM1
13 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.87 TNF TLR2 IL1B
14 response to hypoxia GO:0001666 9.87 TLR2 ICAM1 ADA
15 protein kinase B signaling GO:0043491 9.84 TNF IL1B CCL2
16 acute-phase response GO:0006953 9.84 LBP IL6 CRP
17 positive regulation of nitric oxide biosynthetic process GO:0045429 9.84 TNF ITGB2 IL1B ICAM1
18 negative regulation of neurogenesis GO:0050768 9.82 TNF IL6 IL1B
19 embryonic digestive tract development GO:0048566 9.8 TNF CXCL8 ADA
20 positive regulation of interleukin-8 production GO:0032757 9.8 TNF TLR2 LBP IL1B
21 toll-like receptor 4 signaling pathway GO:0034142 9.79 LBP ITGB2 ITGAM
22 positive regulation of glial cell proliferation GO:0060252 9.79 TNF IL6 IL1B
23 positive regulation of superoxide anion generation GO:0032930 9.78 ITGB2 ITGAM CRP
24 response to glucocorticoid GO:0051384 9.77 TNF IL6 IL10
25 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.77 TNF IL1B IL10
26 positive regulation of interleukin-6 production GO:0032755 9.77 TNF TLR2 LBP IL6 IL1B
27 negative regulation of growth of symbiont in host GO:0044130 9.76 TNF LBP IL10
28 positive regulation of chemokine production GO:0032722 9.76 TNF TLR2 LBP IL6
29 cellular response to lipopolysaccharide GO:0071222 9.76 TNF LBP IL6 IL1B IL10 ICAM1
30 PERK-mediated unfolded protein response GO:0036499 9.74 CXCL8 CCL2
31 negative regulation of interleukin-12 production GO:0032695 9.74 MEFV IL10
32 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.74 ITGB2 ITGAM
33 amyloid-beta clearance GO:0097242 9.73 ITGB2 ITGAM
34 cellular response to lipoteichoic acid GO:0071223 9.73 TLR2 LBP
35 microglial cell activation GO:0001774 9.73 TNF TLR2 ITGB2 ITGAM
36 opsonization GO:0008228 9.72 LBP CRP
37 negative regulation of lipid storage GO:0010888 9.72 TNF IL6 CRP
38 positive regulation of chemokine biosynthetic process GO:0045080 9.71 TNF IL1B
39 endothelial cell apoptotic process GO:0072577 9.71 TNF IL10
40 regulation of establishment of endothelial barrier GO:1903140 9.71 TNF IL1B
41 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.7 TNF ICAM1
42 negative regulation of cytokine secretion involved in immune response GO:0002740 9.7 TNF IL10
43 positive regulation of neuroinflammatory response GO:0150078 9.7 TNF IL6 IL1B
44 positive regulation of fever generation GO:0031622 9.69 TNF IL1B
45 sequestering of triglyceride GO:0030730 9.68 TNF IL1B
46 positive regulation of neutrophil degranulation GO:0043315 9.68 ITGB2 ITGAM
47 negative regulation of dopamine metabolic process GO:0045963 9.68 ITGB2 ITGAM
48 cellular extravasation GO:0045123 9.67 TNF ITGB2
49 receptor biosynthetic process GO:0032800 9.66 TNF IL10
50 positive regulation of prostaglandin-E synthase activity GO:2000363 9.65 ITGB2 ITGAM

Molecular functions related to Peritonitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 TNF TLR2 MEFV CRP B2M AQP1
2 cytokine activity GO:0005125 9.43 TNF IL6 IL1B IL10 CXCL8 CCL2
3 lipopeptide binding GO:0071723 9.32 TLR2 LBP
4 complement component C3b binding GO:0001851 8.8 ITGB2 ITGAM CR1
5 protein binding GO:0005515 10.13 TNF TMEM67 TLR2 MUC16 MEFV LBP
Sources

Sources for Peritonitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....